



Post Authorisation Assessments

Animeloxan 1.5 mg/ml Oral Suspension for Dogs Vm 24745/3000

February 2026	Submission of a Ph. Eur. CEP for an active substance. Submission of a Ph. Eur. CEP for an active substance.
18 December 2025	Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible.
16 December 2025	Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex.
09 May 2024	Repeat use to add 2 CMS.
23 January 2024	Update in line with latest template.
22 December 2023	Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex. (NI)
08 December 2023	Addition of a new supplier of the active substance via a Ph. Eur. CEP.
15 November 2022	Change in immediate packaging of the finished product. Change in pack size of the finished product. Change in storage conditions of the finished product. Change in the specification parameters and/or limits of the finished product. Replacement of syringe. Change of a measuring or administration device: - Other changes
03 December 2020	Submission of a new Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.
16 April 2018	Deletion of a packaging site.
28 May 2015	Deletion of a manufacturing site for batch control.
08 January 2015	Addition of a manufacturing site for secondary packaging.
02 September 2014	To extend the shelf life of the finished product, from 2 years to 3 years.
17 January 2014	To change the QPPV details.
13 September 2013	Renewal.
07 December 2012	To change the QPPV details.
29 November 2012	Deletion of a manufacturer of the finished product.
03 August 2011	To add an additional distributor.
22 October 2009	To make some minor changes to the manufacturing process.
27 August 2009	To add a manufacturer of the finished product.

